

Sales (800) 266-7207 EXT 700 | Direct (424) 444-7184

  • GOVERNMENT BUYER
  • CLINICIAN SIGN UP
Work with Us
Pre-IPO Investment
  • Home
  • About Us
    • Our Team
    • Mission & Values
    • Tribal Activism in Public Policy
    • Commitment to Quality & Compliance
    • Partnerships with Clinicians & Healthcare Providers
  • Products
    • All Products
    • Amniotic Tissue Grafts
      • RAMPART (2 Layers)
    • Wound Care Pre-Graft
  • Clinical Resources
    • Clinical Case Studies
    • Clinician Sign Up
  • News
  • For Patients
    • Amniotic Skin Grafts FAQs
  • Account Sign Up
  • Home
  • About Us
    • Our Team
    • Mission & Values
    • Commitment to Quality & Compliance
    • Partnerships with Clinicians & Healthcare Providers
    • Tribal Activism in Public Policy
  • Products
  • Amniotic Skin Grafts FAQs
  • Clinical Case Studies
  • News
  • Government Buyer
  • Opportunities
    • Pre-IPO Investment
    • Work With Us

CMS Confirms Government-to-Government Receipt of Tribal Real-World Evidence Submission for Rampart™ DL Matrix

Jan 17, 2026 | News

The Centers for Medicare & Medicaid Services has issued formal Government-to-Government receipt confirmation for the Tribal Biotechnology & Health Consortium’s post-market clinical validation evidence submission on Rampart™ DL Matrix (Q4347), submitted...

Tribal Consortium Commences Sovereign Enforcement Activity to Protect Tribal Authority Over the Rampart™ Product Line

Jan 5, 2026 | News

Following the formal federal identification of Rampart™ DL Matrix (Q4347) as a tribally owned product in the December 15, 2025 CMS Federal Register publication, Clear Health Pass Holdings, in its capacity as Authorized Tribal Agent for the Tribal Biotechnology...

CMS Federal Register Identifies Rampart™ DL Matrix as Tribally Owned in CY 2026 Medicare Physician Fee Schedule Policy Update

Dec 15, 2025 | News

The Centers for Medicare & Medicaid Services today published its CY 2026 Medicare Physician Fee Schedule Policy Update in the Federal Register, formally identifying Rampart™ DL Matrix (HCPCS Q4347) as a tribally owned product in the federal record of...

Tribal Consortium Issues Sovereign Notice to CMS Requesting Formal Recognition of Tribal Ownership of Q4347

Dec 9, 2025 | News

The Tribal Biotechnology & Health Consortium today transmitted a formal Sovereign Notice to the Centers for Medicare & Medicaid Services, accompanied by an ECHAGA Corporation Board Resolution, requesting that CMS formally recognize the tribal ownership of...

CMS Coverage and Analysis Group Confirms Receipt of Tribal Real-World Evidence Submission

Nov 17, 2025 | News

The Centers for Medicare & Medicaid Services Coverage and Analysis Group today confirmed receipt of the Tribal Biotechnology & Health Consortium’s post-market clinical validation submission for Rampart™ DL Matrix (Q4347) and confirmed it had forwarded...

Tribal Consortium Submits Post-Market Clinical Validation of Rampart™ DL Matrix to CMS as Government-to-Government Evidence

Nov 1, 2025 | News

The Tribal Biotechnology & Health Consortium today submitted the completed post-market clinical validation of Rampart™ DL Matrix (Q4347) to the Centers for Medicare & Medicaid Services and all seven Medicare Administrative Contractors as a formal...
« Older Entries


Join Our

Newsletter

Clear Health Pass™ Clear Health Pass Holdings, LLC (“CHP”) serves as an authorized Tribal Agent for a multi-tribal economic development and sovereign innovation initiative, pursuant to written delegations issued by federally recognized Tribal economic development corporations organized under Section 16 / Section 17 of the Indian Reorganization Act (25 U.S.C. sections 5123-5124).

Quick Resources

Work with Us
Pre-IPO Investment

Setup Your Account Today

  • GOVERNMENT BUYER
  • CLINICIAN SIGN UP

 Call Us

Sales (800) 266-7207 EXT 700
Direct (424) 444-7184

Clear Health Pass Wound Care © copyright 2024 All Rights Reserved

  • Sitemap
  • Terms and Conditions